TRIB vs. ICCC, AWH, OCX, CDIO, BMRA, MYMD, VRAX, NAVB, IDXX, and LNTH
Should you be buying Trinity Biotech stock or one of its competitors? The main competitors of Trinity Biotech include ImmuCell (ICCC), Aspira Women's Health (AWH), OncoCyte (OCX), Cardio Diagnostics (CDIO), Biomerica (BMRA), MyMD Pharmaceuticals (MYMD), Virax Biolabs Group (VRAX), Navidea Biopharmaceuticals (NAVB), IDEXX Laboratories (IDXX), and Lantheus (LNTH). These companies are all part of the "diagnostic substances" industry.
ImmuCell (NASDAQ:ICCC) and Trinity Biotech (NASDAQ:TRIB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, community ranking, media sentiment, profitability, risk, dividends, earnings and institutional ownership.
ImmuCell has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Trinity Biotech has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500.
ImmuCell has higher earnings, but lower revenue than Trinity Biotech. ImmuCell is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.
13.5% of ImmuCell shares are held by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are held by institutional investors. 6.6% of ImmuCell shares are held by company insiders. Comparatively, 8.2% of Trinity Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Trinity Biotech had 5 more articles in the media than ImmuCell. MarketBeat recorded 8 mentions for Trinity Biotech and 3 mentions for ImmuCell. Trinity Biotech's average media sentiment score of 1.59 beat ImmuCell's score of 0.46 indicating that ImmuCell is being referred to more favorably in the media.
Trinity Biotech received 202 more outperform votes than ImmuCell when rated by MarketBeat users. However, 73.33% of users gave ImmuCell an outperform vote while only 71.30% of users gave Trinity Biotech an outperform vote.
ImmuCell has a net margin of -18.31% compared to ImmuCell's net margin of -37.96%. ImmuCell's return on equity of 0.00% beat Trinity Biotech's return on equity.
Summary
Trinity Biotech beats ImmuCell on 8 of the 15 factors compared between the two stocks.
Get Trinity Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRIB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TRIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Trinity Biotech Competitors List
Related Companies and Tools
